Gemini Therapeutics, Inc.

Disc Medicine, Inc. presented Phase II data for bitopertin in erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP) showing consistent and sustained suppression of a metabolite that c

Strong clinical trial readouts can lead to surging stock prices and big follow-on public offerings (FOPOs), and in a less rocky market failed trial readouts mean that a biopharma company’s stock price

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Disc Goes Public As Gemini Downshifts F

The biopharmaceutical industry showed in multiple ways during the second week of August how a rising tide lifts all ships. Signs that the US may be able to avoid a recession – low unemployment rates a